NOVAVAX INC (NVAX) earnings date
Feb 25, 2027, before open estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 45% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 37 days, typically, give or take 10 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Thu, Nov 5, 2026 | before open | 36 | 8-K |
| Q2 FY2026 | Thu, Aug 6, 2026 | before open | 37 | 8-K |
| Q1 FY2026 | Wed, May 6, 2026 | before open | 36 | 8-K |
| Q4 FY2025 | Thu, Feb 26, 2026 | before open | 57 | 8-K |
| Q3 FY2025 | Thu, Nov 6, 2025 | before open | 37 | 8-K |
| Q2 FY2025 | Wed, Aug 6, 2025 | before open | 37 | 8-K |
| Q1 FY2025 | Thu, May 8, 2025 | before open | 38 | 8-K |
| Q4 FY2024 | Thu, Feb 27, 2025 | before open | 58 | 8-K |
What they guided beta
| Q3 FY2026 | "Raises full-year 2026 Non-GAAP Adjusted Total Revenue by $145 million to $400 million at mid-point and improves GAAP Combined R&D and SG&A expense guidance by $5 million at mid-point" exhibit |
| Q3 FY2026 | "Novavax is eligible to receive an additional milestone of $225 million upon a U.S. commercial launch of a CIC vaccine following successful completion by Sanofi of clinical and U.S. FDA regulatory requirements. o Novavax is eligible to receive royalties in the high single digits to sub-teens as a percentage of Sanofi’s global net sales on a CIC product(s). o Manufacturing technology transfer to Sanofi for Nuvaxovid™ is expected to be completed in mid-2027, which would trigger a $75 million milestone payment to Novavax. o In August 2026, Novavax’s commercial partners received approvals for the X" exhibit |
| Q3 FY2026 | "Licensing royalties and other revenue of $43 million in the third quarter of 2026 were 25% lower than the same period in 2025 driven primarily by a $42 million reduction year-over-year in research and development (R&D) reimbursement revenue as Novavax nears completion of its support of Sanofi Nuvaxovid clinical support for postmarketing commitments." exhibit |
| Q3 FY2026 | "Financial Framework Improves Full Year 2026 Financial Guidance Novavax improved its Full Year 2026 Financial Guidance at mid-point by reducing Combined R&D and SG&A Expense guidance while maintaining Non-GAAP Combined R&D and SG&A Expense guidance and expects to achieve the following results: $ in millions Full Year 2026 (as of Nov 5 2026) Full Year 2026 (as of Aug 6 2026) Combined R&D and SG&A Expenses $375 - $395 $370 - $410 Less: R&D Reimbursements ($60) ($60 - $70) Non-GAAP Combined R&D and SG&A Expenses $315 - $335 $310 - $340 Non-GAAP Combined R&D and SG&A Expenses exclude R&D Reimbursem" exhibit |
| Q3 FY2026 | "Raises Full Year 2026 Revenue Framework For 2026, Novavax raised its 2026 Revenue Framework and expects to achieve the following results for Adjusted Total Revenue. 4 $ in millions Full Year 2026 (as of Nov 5, 2026) Full Year 2026 (as of Aug 6, 2026) Nuvaxovid Product Sales 1 $40 - $50 $35 - $45 Adjusted Supply Sales 2 $50 - $60 $45 - $55 Sanofi CIC Milestone 3 $125 No guidance Adjusted Licensing, Royalties and Other Revenue 4 $170 - $180 $155 - $175 Adjusted Total Revenue 5 $385 - $415 $235 - $275 Sanofi Supply Sales, Sanofi Royalties and future Sanofi Milestones No guidance No guidance Novav" exhibit |
| Q2 FY2026 | "Reported total revenue of $57 million for the second quarter of 2026 and raised full- year 2026 Revenue Framework" exhibit |
| Q2 FY2026 | "Completion of manufacturing technology transfer to Sanofi expected in mid-2027 and would trigger a $75 million milestone payment to Novavax" exhibit |
| Q2 FY2026 | "On track to advance C. difficile vaccine program into the clinic as early as 2027" exhibit |
| Q2 FY2026 | "Initiation of this trial in the U.S. or European Union will trigger a $125 million milestone to Novavax. o Manufacturing technology transfer to Sanofi for Nuvaxovid™ is expected to be completed in mid-2027, which would trigger a $75 million milestone payment to Novavax." exhibit |
| Q2 FY2026 | "Improves Full Year 2026 Financial Guidance" exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/NVAX
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/NVAX
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/NVAX/"><img src="https://veritasdata.dev/embed/NVAX.svg" alt="NVAX earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/NVAX/)
Script
<script async src="https://veritasdata.dev/embed/NVAX.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/NVAX"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.